Pharma Tech Outlook: Pharma Tech Magazine

Cerba Research: Setting New Standards For Exemplary Clinical Development

Top 10 Virology Tech Companies in Europe - 2020


Emerging infectious diseases caused by viruses have assumed great public health significance in the recent past. During the last three decades, almost twenty new viral pathogens have been detected. Some of these have already caused substantial mortality, morbidity and economic loss across the globe. The recent COVID-19 pandemic caused due to the spread of coronavirus unequivocally demonstrated the rapidity with which new viruses can travel across the world and inflict misery—is the most significant public health challenge in the current millennium so far.

As viral infections diagnosis demands novel, cheaper and rapid technologies to overcome present constraints, the current gold standard for diagnosis of viral infections is based on pathogen-targeted nucleic acid identification. Thus, it cannot discern infectious stages from latent ones, and it demands time-consuming adjustments when mutations occur, or new emerging viruses are to be included in the diagnostic protocols. Now, developing viral vaccines and antiviral drugs is exceptionally challenging. Due to complex nature, virologists first need to solve the virus structure and understand its life cycle. This knowledge is what enables the foundation of effective vaccines and the search for drugs that can inhibit or block a crucial step in the virus’ life cycle. Virology Tech companies offer novel technology capable of identifying viral particles and asses their infective potential. These companies provide personalized treatment to the patients, reducing the use of not effective antibiotics, increasing safety in blood transfusions, allowing a quick and trustworthy response to emergencies, reducing the spread of viral infections, reducing costs per analysis and screening of a wide range of pathogens.

Through this edition of Pharma Tech Outlook, our editorial team wishes to highlight the top players within the virology tech industry, aiming to showcase eventful avenues in the arena through a peer to peer knowledge delivery approach.

Pharma Tech Outlook is proud to present its list of “Top 10 Virology Tech Companies in Europe - 2020.”

    Top Virology Tech Companies in Europe

  • Led by a group of motivated individuals committed to improve health via diagnostic services, Cerba Research empowers pharma, biotech companies, NGOs and governments, in the virology space to develop personalized medicines that will potentially change the lives of people worldwide for the better. Cerba Research primarily focuses on accelerating clinical trials and therapies through the development of highly specialized custom assays, biomarker expertise, and routine and specialty testing technologies across multiple therapeutic areas. Cerba Research is well informed about the developments in the field of pharmaceuticals and routine diagnostics

  • Myriade is a French company created in 2017 that develops an innovative nanoscale imaging technology. Based on the principles of interferometry, Videodrop makes it possible to measure the size and concentration of nanoparticles in the range of 30 nanometers and 10 microns without labelling, in near real time by utilising just five microlitres of a sample. The device is easy-to-use, very accessible, and works expeditiously. Additionally, Videodrop continually monitors viral vector solutions for gene and cell therapy, seamlessly distinguishes the different types of extracellular vesicles to vectorise, diagnose, or treat, and analyses phages solutions used for phagotherapies

  • PeproTech was established in 1988 by a group of scientists who decided to focus their efforts on the development and production of recombinant cytokines for life-science research. Today, PeproTech is a world leader in supplying high quality cytokine products including E.coli, insect, and mammalian cell-derived recombinant proteins, their monoclonal/polyclonal antibodies, ELISA Development Kits, Cell Culture Media/Supplements, and other cytokine-related reagents

  • Yposkesi is a leading contract development and manufacturing organisation (CDMO) for gene therapy vector manufacturing. Founded in 2016 by AFM-Telethon and the SPI fund, the company provides integrated services for bioprocess development (USP & DSP) from small/pilot to large-scale production, analytical development, GMP manufacturing of lentiviral and AAV vectors, and regulatory support. The company’s facility consists of a 5000 square metre building, operating multiple manufacturing suites for the bulk drug substance. Capitalising on the more than 30 years of expertise from Genethon, Yposkesi invests significantly in innovation in bioprocessing to deliver high-quality projects cost-effectively. Yposkesi has also entered into several strategic partnerships

  • BIA Separations

    BIA Separations

    BIA Separations is a worldwide provider of solutions for biopharmaceutical companies. The company's prepacked chromatographic columns enable high-speed purifications up to industrial-scale (non cGMP and cGMP compliant) of large biomolecules such as viruses (rAAV, adenovirus, influenza, lentivirus, bacteriophages), plasmid DNA and larger proteins (mAbs, IVIG, IgM, PEGylated proteins)

  • Cepheid


    Over a decade ago, Cepheid set the standard for innovation in automated molecular diagnostics with its first system. And now, even with the largest installed base of any molecular platform, Cepheid is constantly innovating and evolving its capabilities. The company's technology has been heralded as game-changing by healthcare leaders world-wide

  • ELITechGroup


    ELITechGroup is a privately held group of worldwide manufacturers and distributors of in vitro diagnostic equipment and reagents. By bringing together IVD specialty companies that offer innovative products and solutions, ELITechGroup has become a major contributor in advancing clinical diagnostics to laboratories in the proximity market, those operating closer to the patient

  • Elsevier


    Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, and deliver better care. The company help researchers to make discoveries, collaborate with their colleagues and give them the knowledge they need to find funding

  • Transgene


    Transgene is a clinical-stage biotechnology company focused on designing and developing novel immunotherapeutics. The company participates in exchanges and collaborations to develop its R&D expertise, product portfolio, and processes. Transgene is engaged in several collaborative programs with public and private partners, in France and worldwide

  • VCN Biosciences

    VCN Biosciences

    VCN Biosciences SL is a privately-owned company focused in the development of new therapeutic approaches for tumors that lack effective treatment. The company uses an oncolytic adenovirus technology platform to design highly selective and efficient agents that replicate and self-amplify exclusively in tumor cells. The selectivity of VCN oncolytic adenoviruses allows their systemic administration, which is especially relevant for the treatment of disseminated cancer